"When we looked at the same phenotypic data, but focusing on each immunochemistry protein markers, we had 10 patients with AR negative tumor with clearly worse prognosis, and synaptophysin-positive ...

"At the University of Michigan, we've actually started to offer prostate MRI without contrast for patients on active surveillance, which has been a really exciting change," says Benjamin Pockros, MD, ...

“We are pleased that a first patient has been imaged in the CA-NINE trial, which supports potential label expansion for TLX250-CDx into recurrent, metastatic disease,” says David N. Cade. The first ...

"The radiologist more than ever has to be part of the care team," says Phillip H. Kuo, MD, PhD, FACR. In this interview, Phillip H. Kuo, MD, PhD, FACR, discusses the key elements of a PSMA-PET report ...

"I would say the take-home message is that we found that from a patient-centered orientation, telehealth for new and established patients have comparably high satisfaction scores but provide ...

"The addition of radium-223 to SABR metastasis-directed therapy in low-volume bone-metastatic hormone-sensitive prostate cancer does not delay progression of disease in the RAVENS study," said Ana ...

“The toxicity benefits of aggressive margin reduction persist beyond the acute phase post-SBRT," the authors wrote. Aggressive margin reduction with MRI-guided stereotactic body radiotherapy (SBRT) ...

In total, the phase 3 UTOPIA trial plans to enroll 87 patients with LG-IR-NMIBC to assess the safety and efficacy of UGN-103. The first patient has been dosed in the phase 3 UTOPIA trial (NCT06331299) ...

Zaorsky discusses the patient safety misconceptions around radiotherapy for RCC, and considering patient-reported outcomes in future randomized controlled trials. New data presented at the American ...

Pastuszak discusses the evolving nature of understanding how testosterone therapy post-radiation for prostate cancer may beneficial or harmful to patients, and how to navigate the decision. Though ...

At the 24-month time point, patients who received apalutamide had a 23% reduction in the risk of death compared with patients who initiated enzalutamide. Apalutamide (Erleada) was found to provide a ...

Soumyajit Roy, MS, MBBS, explains how findings showing 5-year biochemical recurrence status may predict prostate cancer cure should alter the clinician-patient interaction. The implication of patient ...